Why community doses are lower: No FDA approval means conservative self-titration
We did not restrict our study to patients who were highly adherent with their medication either, which may better reflect the utility of these medications in every day clinical practice. White and colleagues collected electronic health records and health insurance claims data from 2,405 adults aged 18 years and older receiving care at a large health care system in western Pennsylvania who were dispensed a GLP-1 receptor agonist from 2011 to 2018 (mean age, 48 years
Our data suggest that hypermethylation of the 25-hydroxylases, 1--hydroxylase enzymes, and the vitamin D receptor promoter, accompanied by hypomethylation of CYP24A1, leads to impaired expression and possibly a predisposition to VD deficiency/inadequacy
Unlike one-size-fits-all approaches, PlexusDx treatment aligns with your unique genetic and metabolic profile from day one
Michigan does not currently have a state mandate requiring insurers to cover obesity medications or GLP-1 treatments